StemCell Therapy

Objective:To estimate the annual cost associated with obstetric events in women of reproductive age with immune-mediated inflammatory diseases, from the perspective of the National Healthcare System.

Methods:A cost-analysis was developed to estimate the impact associated with obstetric events in women of reproductive age with psoriasis (PSO), psoriatic arthritis (PsA), rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA). The analysis considered complications during fertility and conception, in pregnancy and in the postpartum. All parameters were validated and agreed by a multidisciplinary expert panel. Unitary costs (, 2019) were obtained from national, local databases.

Results:During fertility and conception, an annual cost per patient of 229 was estimated for a preconception consultation in a patient with PSO, of 3,642 for a preconception consultation in patients with PsA, RA and axSpA and 4,339 for assisted reproduction. Women with complications in pregnancy had an annual cost per patient of 1,214 for a miscarriage in the first trimester, 4,419 for a late miscarriage in the second trimester, 11,260 for preeclampsia 3,188 for restricted intrauterine growth and 12,131 for threat of premature delivery. In the postpartum, an annual cost per patient of 120,364, 44,709, and 5,507 were estimated associated with admissions to neonatology of premature infants of <28, 28-32 and 33-37 weeks, respectively.

Conclusions:This analysis provides insight on the economic burden of complications associated with women of reproductive age for immune-mediated diseases (PSO, PsA, RA, axSpA). Individualization of treatment, additional and close monitoring may reduce the risk and burden of these complications.

Keywords:Anlisis de costes; Complicaciones materno-fetales; Cost-analysis; Enfermedades reumticas; Espaa; Eventos obsttricos; Maternal-foetal complications; Obstetric events; Rheumatic diseases; Spain.

See the original post here:
Economic Impact of Obstetric Events on Women of Reproductive Age Living With Psoriatic Arthritis, Rheumatoid Arthritis, Axial Spondyloarthritis and...

This article was originally published here

Rheumatol Int. 2020 Nov 30:1-10. doi: 10.1007/s00296-020-04751-w. Online ahead of print.

ABSTRACT

Nationwide lockdowns during SARS-CoV-2 (COVID-19) can compromise mental health and psychological wellbeing and limit opportunities for physical activity (PA), particularly in clinical populations, such as people with rheumatoid arthritis (RA), who are considered at risk for COVID-19 complications. This study aimed to investigate associations between PA and sedentary time (ST) with indicators of mental health and wellbeing in RA during COVID-19 lockdown, and examine the moderation effects of self-isolating. 345 RA patients completed an online questionnaire measuring PA (NIH-AARP Diet and Health Study Questionnaire), ST (International Physical Activity Questionnaire-Short Form), pain (McGill Pain Questionnaire and Visual Analogue Scale), fatigue (Multidimensional Fatigue Inventory), depressive and anxious symptoms (Hospital Anxiety and Depression Scale), and vitality (Subjective Vitality Scale) during the United Kingdom COVID-19 lockdown. Associations between PA and ST with mental health and wellbeing were examined using hierarchical multiple linear regressions. Light PA (LPA) was significantly negatively associated with mental fatigue ( = .11), depressive symptoms ( = .14), and positively with vitality ( = .13). Walking was negatively related to physical fatigue ( = .11) and depressive symptoms ( = .12) and positively with vitality ( = .15). Exercise was negatively associated with physical ( = .19) and general ( = .12) fatigue and depressive symptoms ( = .09). ST was positively associated with physical fatigue ( = .19). Moderation analyses showed that LPA was related to lower mental fatigue and better vitality in people not self-isolating, and walking with lower physical fatigue in people self-isolating. These findings show the importance of encouraging PA for people with RA during a lockdown period for mental health and wellbeing.

PMID:33258004 | PMC:PMC7703721 | DOI:10.1007/s00296-020-04751-w

Here is the original post:
Different types of physical activity are positively associated with indicators of mental health and psychological wellbeing in rheumatoid arthritis...

There are very few things that bring more joy in our lives than having a pet dog. If youre a pet parent, you must be already familiar with the fantastic health benefits of having a dog at home. Also, house pets have a positive impact on your mental well-being and can even help you cope with grief and loneliness. Once they become a part of your family, its your responsibility to care for them.

If we could have our way, wed want our canine companions to be a part of our lives forever. But, unfortunately, theyre going to grow old and become fragile and weak. Activities that once happened naturally, such as jumping down the stair and running around in the park, are going to need more effort. On top of that, your dog might become susceptible to various chronic diseases.

Canine osteoarthritis, a chronic condition, can cause extreme pain and discomfort to your dog. It affects at least 20% of dogs whore over one-year-old. While theres no way to completely cure canine arthritis, theres a lot you can do to help your dog when theyre in pain.

In this blog, well dive deeper into the topic of canine arthritis and understand what causes it. Well also outline the signs and symptoms you should watch out for, as well as recommend a few pain management techniques. Lets get started.

Canine arthritis is a chronic ailment that causes stiffness and joint pain in dogs. It happens when the cartilage tissue protecting the bones in a joint starts degenerating. In a healthy joint, the cartilage between the bones is lubricated with a fluid. This prevents the bones from coming in direct contact and rubbing together.

If the cartilage tissue starts decaying as a result of an injury or old age, the bones come in direct contact with each other. As the bones rub together, it causes extreme pain and inflammation in the joints. It can also result in the growth of new bones (called osteophytes) that further intensify the pain.

Moreover, when the cartilage cells degenerate, they release certain enzymes that cause inflammation of the joints. It also leads to excessive fluid buildup in the joints. All these factors amplify the pain and can even result in mobility issues as well as muscular atrophy.

While canine osteoarthritis can affect dogs of any age and breed, there are a few potential risk factors such as:

There isnt much you can do to prevent your dog from developing a chronic ailment like arthritis. However, the earlier you notice their symptoms and consult a veterinarian, the better their quality of life will be.

As a dog parent, here are a few signs and symptoms you should watch out for:

Its worth mentioning here that dogs are often very adept at hiding their pain. Thats why you need to be extra cautious and start paying attention to their gait and posture the moment you notice any signs of pain in your dog.

Unfortunately, canine arthritis is an irreversible degenerative disease. Once the cartilage cells start dying, theres no way to regenerate them and make the joints healthy again. Having said that, you can use a wide array of pain-relieving techniques to help dogs with osteoarthritis.

Here are a few things you can do to help your dog if they develop osteoarthritis:

The key to managing canine arthritis is to minimize pain and inflammation in the joints. A non-steroidal inflammatory drug (NSAID) such as Previcox, treats arthritic pain in dogs by reducing inflammation. However, the symptoms of canine arthritis overlap with those of several other ailments.

Your dog might just be in pain because of a bone injury. Or the symptoms could be an indication of a more serious disease such as cancer. Thats why it is important to first consult your vet and ask for a suitable treatment plan.

Typically, the doctor will conduct a physical exam of your dogs body. Theyll also likely recommend an X-ray of the limbs. Depending on whether they detect signs of arthritis, theyll recommend the course of treatment.

Consult your vet to create a balanced and nourishing diet plan thats rich in anti-inflammatory and whole foods such as turmeric, ginger, fatty fishes, and leafy vegetables. You could also consider including Omega-3 supplements in their diet. Make sure you avoid inflammatory and unhealthy foods that could trigger more pain.

If your dog is in pain, theyll become unwilling to go on walks or engage in regular physical activities. However, they dont get adequate exercise; theyll likely put on more weight, potentially becoming obese, and developing more pain. Make sure you talk to your vet and work out a less taxing exercise routine for your dog.

Depending on your dogs age and physical health, the vet might suggest pain-relieving therapies such as acupuncture, hydrotherapy, physiotherapy, etc. These techniques can go a long to alleviate the pain and improve your four-legged friends overall quality of life.

Recent studies have also shown that CBD oil can help relieve arthritic pain in dogs. However, it could also have potential side effects such as gastrointestinal disorders. Make sure you consult your vet and ask them to prescribe the suitable dosage for your dog.

Have you used any other pain management techniques to help an arthritic dog? Share your suggestions in the comments section below.

Visit link:
Canine arthritis Its a real thing that pet parents need to be prepared for - TechEngage

Visit the News Hub

In mouse study, loss of molecule contributes to disease while surplus reduces symptoms

Researchers at Washington University School of Medicine in St. Louis have found, working in mice, that when the FoxO1 gene is knocked out, the animals develop osteoarthritis. But when levels of the FoxO1 molecule are increased, the animals exhibit less cartilage damage.

Osteoarthritis is one of the most common problems associated with aging, and although there are therapies to treat the pain that results from the breakdown of the cartilage that cushions joints, there are no available therapies to modify the course of the disease.

However, working in a mouse model of the disorder, researchers at Washington University School of Medicine in St. Louis have found that a molecule previously linked to diabetes, cancer and muscle atrophy also seems to be involved in the development of osteoarthritis and may be a useful treatment target.

When the gene involved, FoxO1, is knocked out in mice, the animals develop osteoarthritis. But when the researchers increase the levels of the FoxO1 molecule in mice that are developing osteoarthritis, the animals exhibit less cartilage damage.

The study is available online in Proceedings of the National Academy of Sciences.

Osteoarthritis, or joint degeneration, is a disease that affects more than 32 million people in the U.S. alone but that does not have a medical therapy to alter its progression, said senior investigator Regis J. OKeefe, MD, PhD, the Fred C. Reynolds Professor of Orthopaedic Surgery and head of the Department of Orthopaedic Surgery. A better understanding of the fundamental processes involved in osteoarthritis and the degeneration of cartilage is required if were going to be more successful in treating this very common and very expensive disorder.

OKeefe said that commonly, people with osteoarthritis have suffered knee injuries that damaged the knees meniscus. Over time, arthritis then can develop in the joint.

Unlike skin or bone or other organs that can regenerate in response to injury, cartilage has very little regenerative potential, he said.

However, when the mice in these experiments had elevated levels of the FoxO1 molecule, osteoarthritiss progress was slowed or even reversed. The researchers believe the molecule interferes with cartilage damage and the development of arthritis by enhancing a process called autophagy in the arthritic joint. Autophagy is the bodys way of clearing out damaged tissue. In these experiments, the researchers found that autophagy was disrupted in the mice with reduced levels of FoxO1 and that the process was enhanced in animals with higher levels of the molecule.

In other words, maintaining a higher level of autophagy seemed to be beneficial to maintaining these cartilage cells and, thus, maintaining a healthy knee joint, said co-corresponding author Jie Shen, PhD, an assistant professor of orthopedic surgery.

OKeefe said that raises the possibility of delivering FoxO1 to arthritic joints through nanotechnology as a way to regulate autophagy and keep joints healthier.

In mice with injuries that typically progress to become osteoarthritis, the knee joints still appear normal about a week after injury, OKeefe explained. But when we measure autophagy in the cartilage after injury to those same knee joints, although the joints themselves look fine, the autophagy process already is shut off. The injury completely turns it off, and once autophagy is off, the cartilage begins to degenerate.

He said if FoxO1 can alter that process in people, protecting cartilage from damage as it does in mice, it eventually may be possible to prevent or delay millions of future knee and hip replacement surgeries.

Wang C, Shen J, Ying J, Xiao D, OKeefe RJ. FoxO1 is a crucial mediator of TGFB/TAK1 signaling and protects against osteoarthritis by maintaining articular cartilage homeostasis. Proceedings of the National Academy of Sciences, Nov. 16, 2020.

This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH). Grant numbers R01 AR069605, T32 AR060719 and P30 AR057235.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

The rest is here:
Gene that protects against osteoarthritis identified Washington University School of Medicine in St. Louis - Washington University School of Medicine...

Jennifer May, M.D., Prairie Doc Published 9:33 p.m. CT Dec. 3, 2020

Jennifer May, M.D.(Photo: Submitted)

As a rheumatologist, I often get the question, What do you do? According to my kids, their mom does something with joints. At the conclusion of patient visits, when I propose a diagnosis such as polymyalgia rheumatica or PMR, I often hear, What is that? The fact is most people do not think about rheumatology until they need a rheumatologist. And then, learning the lingo about disease, medications, and lab monitoring can be a challenge.

Rheumatology is a relatively new specialty in the world of medicine. Focus on the disease in America began in the early 1920s with initial definition and discovery, followed by the famous breakthrough of cortisone at Mayo Clinic in 1950, and grew to a deeper scientific understanding of arthritis diseases today. Treatments have progressed from cortisone and aspirin to immune system modification with biologic medications. Future therapies will involve genetics, engineering new cartilage, and creating cells that rheumatologists will command to do our bidding upon the immune system.

Today we work to manage autoimmune diseases such as rheumatoid arthritis or lupus with medications that adjust the immune system response. Symptoms that can occur in association with some of these diseases are rashes, joint swelling, fevers, lung problems, and kidney issues. By adjusting the immune system, we can change the symptoms, hopefully lessening their impact on the patient.

In our fast-paced world, we often want answers and quick solutions to our problems. However, rheumatology cases require persistence. There are no blood tests that specifically diagnose the problem. Rheumatologists must take time to talk with and examine the patient. We gather additional information from labs tests, studies, and x-rays. Once all the data is available, sometimes the condition is clear. But other times, the case is more challenging and requires several visits before making a firm diagnosis.

Like most health providers, I enjoy solving patient problems and making a diagnosis. We get satisfaction from figuring things out and our reward comes when a treatment improves a patients function or quality of life. Our goal in rheumatology is to help patients achieve remission, or better yet, to predict who is likely to get rheumatoid arthritis in hopes of preventing it from starting in the first place.

So, when patients look at me with that expression that asks rheuma-what?, they dont necessarily want to hear about the science of what I do. Instead, I assure them that we will keep working together with the same goal: To get the immune system to quiet down, and help the patient feel better so they can get back to life.

Jennifer May, M.D. is a contributing Prairie Doc columnist. She practices rheumatology in Rapid City. Prairie Doc can be seenon SDPB most Thursdays at 7 p.m.

Read or Share this story: https://www.argusleader.com/story/news/brandon/2020/12/03/learning-what-rheumatologist/3820369001/

See the rest here:
Learning what it is to be a rheumatologist - Argus Leader

December 1 is Giving Tuesday, a holiday created to highlight nonprofits and other organizations that work locally and globally to spread generosity and giving. The movement began in New York City in 2012 and has since flourished into an international event. The movement continues to grow in year-over-year donation volume, reach, and impactdriving increased donations and behavior change, said GivingTuesday.org.

In 2019, at least $1.97 billion were donated in 24 hours [during Giving Tuesday] in the U.S. alone, with 13 percent of the adult population participating in some waya record-setting day. Around the world, the majority of people aware of Giving Tuesday say that it has inspired them to be more generous, the nonprofit added.

Its hard to quantify or overestimate the power of goodwill, particularly this year when the holidays will be so different, for so many. A gesture of kindness, big or small, can make a lot of difference to a friend or co-worker, neighbors or children, or those less fortunateits the joy of giving that warms the heart and makes memories for years to come.

This year, which is like no other in our lifetime, is a real game-changer for charities and the people they benefit, though. Its a diverse cross-section of Americansincluding cannabis industry memberswho keep giving. And thank goodness for that, because this year every dollar counts. The help you give will be warmly appreciated and rememberedso, give until it feels good.

Vape manufacturer PAX Labs partnered with nonprofit Last Prisoner Project to host a fundraiser benefiting more than 40,000-plus people in prison for cannabis offenses. Today and tomorrow, December 12, 2020, every donation of $25 or more will be entered to win one of twenty free PAX 3 Complete Kit cannabis vaporizers.

The PAX fundraiser directly benefits LPP, which recently helped win clemency for Americas longest serving, non-violent cannabis offender, Richard DeLisi. Anyone who would like to donate for a chance to win one of the free PAX vape kits (or any amount) should visit PAX Giving Tuesday.

Edibles manufacturer MONDO Meds is offering a free jar of its CBD-infused powder supplement to firefighters, healthcare, and government workers. Each 4-ounce jar contains 150mg CBD in a rich, powdered formula that can be added to beverages or food. Front line workers may contact [emailprotected] to request a free jar ($40.00 MSRP), when they email a picture of their government ID and best delivery address.

With many essential workers serving on the front lines of multiple natural disasters and experiencing so much anxiety and stress, CBD brands are also making contributions aimed at showing appreciation to these heroes.

As an official Impact Sponsor for the Arthritis Foundation, Charlottes Webs CBDMEDIC brand will match individual donations made to the Arthritis Foundation on Giving Tuesday up to a total sum of $50,000. Those who donate $50 or more will receive a gift of CBDMEDICs Arthritis Aches and Pain Relief Cream.

Especially in these uncertain times, due to the pandemic, it is vitally important that businesses and their brands step up and support nonprofits like the Arthritis Foundation this Giving Tuesday, said Charlottes Web Chief Executive Officer Deanie Elsner, We encourage everyone who is able to do so to give this Giving Tuesday to the Arthritis Foundation.

If you would like to donate to the Arthritis Foundation as part of the CBDMEDIC fundraiser click here for more information.

Etain Health, New Yorks only family-run, women-owned and operated, medical marijuana company and lifestyle brand Buy Weed From Women (BWFW) have teamed up for a fundraiser to benefit the Food Bank for New York, a nonprofit that has been working to end food poverty in New Yorks five boroughs for over 36 years.

The collaboration between Etain and BWFW has resulted in the Goods Box, a limited edition collection featuring BWFW merchandise including a long-sleeve tee and face covering and more good surprises. The box goes on sale December 3, at EtainHealth.com and proceeds will benefit the food bank.

See the original post:
December 1 is Giving Tuesday, a holiday created to highlight nonprofits and other organizations that work - mg Magazine

The Global Rheumatoid Arthritis (RA) Drugs Market analysis report published on dataintelo is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=94401

The Global Rheumatoid Arthritis (RA) Drugs Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Rheumatoid Arthritis (RA) Drugs Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Rheumatoid Arthritis (RA) Drugs Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=94401

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Rheumatoid Arthritis (RA) Drugs Market as:Global Rheumatoid Arthritis (RA) Drugs Market Size & Share, by Regions

Global Rheumatoid Arthritis (RA) Drugs Market Size & Share, by ProductsOralInjectionExternal

Global Rheumatoid Arthritis (RA) Drugs Market Size & Share, ApplicationsMedical CarePersonal Care

Key PlayersAbbVieRocheJohnson & JohnsonAmgen, Inc.PfizerMerckBristol-Myers SquibbUCBGlaxoSmithKlineSanofiAbbott LaboratoriesTeva Pharmaceutical

Avail the Discount on this Report @ https://dataintelo.com/ask-for-discount/?reportId=94401

Dataintelo offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

View post:
Rheumatoid Arthritis (RA) Drugs Market 2020 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2025 - Murphy's Hockey Law

The Rheumatoid Arthritis Diagnosis Tests Market grew in 2019, as compared to 2018, according to our report, Rheumatoid Arthritis Diagnosis Tests Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Rheumatoid Arthritis Diagnosis Tests Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Rheumatoid Arthritis Diagnosis Tests Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-rheumatoid-arthritis-diagnosis-tests-market-2020-market-size-share-growth-trends-forecast-2025/#download-sample

The Rheumatoid Arthritis Diagnosis Tests Market is analysed based on product types, major applications and key players

Key product type:Serology TestsMonitoring RA Treatment Efficiency Tests

Key applications:Diagnostic LaboratoriesAmbulatory Surgical CentersHospitals

Key players or companies covered are:AbbottBeckman CoulterEuro DiagnosticaRocheQiagenSiemens HealthcareThermo Fisher ScientificBio Rad LaboratoriesAviva Systems Biology

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-rheumatoid-arthritis-diagnosis-tests-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report:1. What is the current size of the Rheumatoid Arthritis Diagnosis Tests Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Rheumatoid Arthritis Diagnosis Tests Market?4. What is the likely market forecast & how will be Rheumatoid Arthritis Diagnosis Tests Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Rheumatoid Arthritis Diagnosis Tests Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

View post:
Rheumatoid Arthritis Diagnosis Tests Market by Analysis, Market Dynamics, Regions, Consumption, Production, Suppliers and Forecast 2026 - Cheshire...

In the first wave of the coronavirus disease 2019 pandemic, patients with axial spondyloarthritis, rheumatoid arthritis, and psoriatic arthritis didnt have an increase in disease activity despite an interruption in in-person interactions.

During the first wave of the coronavirus disease 2019 (COVID-19) pandemic, patients with axial spondyloarthritis (axSpA), rheumatoid arthritis (RA), and psoriatic arthritis (PsA) didnt see any increase in disease activity despite an interruption in in-person interactions, according to research published in Annals of Rheumatic Diseases.

The researchers analyzed patients in the Swiss Clinical Quality Management cohort to understand how partial or complete closure of rheumatology services impacted disease activity as remote consultations were used to partly compensate for the reduced in-person interaction.

Additional factors may also potentially contribute to disease worsening during the pandemic, the authors explained. Some patients may choose to preventively stop immunosuppression out of fear of complications. Moreover, the psychological stress (anxiety about a new disease, economic pressure, less recreational opportunities and so on) encountered during the pandemic should not be underestimated.

The researchers defined 3 study periods: a preCOVID-19 phase from January 1 to February 29, 2020; a COVID-19 phase from March 1 to April 30, 2020; and a postCOVID-19 phase from May 1 to June 30, 2020. Patients who had at least 1 patient-reported disease activity measure in each of the study periods were included.

A few disease activity assessments were used: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for axSpA; the Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5) in RA; and the Patient Global Assessment (PGA) visual analogue scale for disease activity in PsA. The researchers used the following to define a clinically important worsening:

The study looked at 287 patients with axSpA, 248 with RA, and 131 with PsA. The number of visits dropped 52% from 543 in February to 262 in April; however, there was a 129% increase in web-based application entries (521 to 1195) during this time.

In the preCOVID-19 phase, 15% of patients were nonadherent to their medication. While there was a slight increase in nonadherence during the COVID-19 phase, the researchers noted the increase only reached statistical significance among patients with axSpA.

Adherence returned to prepandemic levels in the postCOVID-19 phase, they wrote.

Over the first half of 2020, patient-reported disease activity outcomes were stable. There was a slight decrease during the COVID-19 phase; the decrease was only statistically significant for patients with axSpA (mean BASDAI 3.40 before the pandemic and 3.23 during the pandemic; P = .02). There was disease flare in less than 15% of patients for all 3 diseases, which was not statistically different from the preCOVID-19 phase.

The authors noted that the fact they could only evaluate patients with regular disease activity assessments was a limitation.

This subset using the smartphone app is probably more invested in disease management and the non-compliance figures might be under-represented, they wrote.

Reference

Ciurea A, Papagiannoulis E, Brki K, et al. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. Published online September 22, 2020. doi:10.1136/annrheumdis-2020-218705

Read more from the original source:
Interruptions to In-Person Visits During Pandemic Did Not Negatively Impact Patients With Inflammatory Arthritis - AJMC.com Managed Markets Network

I harassed my GP enough to get it caught early

Meet Georgie.

At age 26, Georgie was diagnosed with rheumatoid arthritis, an autoimmune inflammatory condition that affects up to1% of the population worldwide.

Suffering from such incredible pain every morning that stopped her from doing simple things like getting dressed or brushing her teeth, Georgie sought help. And refused to stop until she got answers.

What we can learn from Georgies story

Georgies story is a positive one, one where the short time to diagnosis (23 months) meant that the disease was caught and treated early, causing minimal damage to her joints. So what contributed to this?

On the one hand, time-lags between initial symptoms and diagnosis for rheumatoid arthritis have universally decreased in recent years (egfrom 24 months in 20002002 to 6 months in 20092011). Key to this has probably been a shift in clinicians knowledge of the disease and the motivation to treat likely tied to their beliefs about the consequences of the disease and the impact of early diagnosis.

At the same time, patient empowerment remains an integral driver to accelerating diagnosis and treatment.

And Georgie is a great example of a patient who empowered herself by asserting her interests.

She had an awareness of her own body and what is normal. So when her doctors initially sent her home, she didnt give up within 2 weeks, she was back, asking for answers. When the blood tests came back normal, she wasnt demoralised. Her awareness, together with the desire to live pain-free, gave her the motivation and confidence to assert her interests in her interactions with healthcare professionals and persist until a referral and diagnosis were reached.

But she shouldnt have to empower herself

Georgies success comes from being assertive and not all patients will be. So what about them? Will they end up with a delayed diagnosis and the consequent joint damage that goes with it?

Communication is key here; and both parties need to be involved. The environment has to engage patients and give them the knowledge, confidence and skills they need to be active players in their care. Which will be necessary to bridgethe gap between patients and doctors and enable them to share the knowledge they each have and help them make informed mutual decisions.

Clearly great strides have been made in rheumatoid arthritis. But we cant pause now; by looking at stories like Georgies, we have to keep assessing the gaps and continuously evolve the environment.

See more here:
The other side of rheumatoid arthritis - PMLiVE

DelveInsight's Rheumatoid Arthritis report states that the therapeutic market is expected to grow because of the launch of emerging drugs in the pipeline however the growth during the forecast period will be dampened because of the entry of biosimilars of blockbuster drugs

LAS VEGAS, Oct. 29, 2020 /PRNewswire/ -- The Rheumatoid Arthritis market report delivers an in-depth understanding of the Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan for the study period of 2017-2030.

Few of the key highlights from the report:

The Biologics segment holds the highest share in the market in terms of revenue; its approximately 90% of the market share. Among the biologics, its anti-TNFs (~68%) have captured the major portion of the market owing to well-established efficacy, safety profile, physicians familiarities, and their long presence in the market. Among the anti-TNFs, etanercept and adalimumab were holding around 50% of the total in the 7MM market share in 2017.

Among the currently approved advanced classes, the growth of anti-TNF, T cell inhibitor, and B cell Inhibitor are expected to be relatively flat mainly due to the entry of biosimilars which ultimately leads to erosion of sales value.

As per DelveInsight's analysts the JAK inhibitor class expected to grow with a significant CAGR during the forecast period owing to market penetration of already approved products, entry and adoption of emerging drugs, and increase in physicians familiarities, and placing of JAK as a treatment option in the first line.

The Biosimilars started entering the United States and EU (i.e. Remicade biosimilars) and due to this sales value has started declining and the impact will be more pronounced when biosimilars/ generics of some blockbuster drugs like Humira (i.e. 2023 in the US), Xeljanz (i.e. 2025 in the US) will going to hit into the market and this will impact the growth of RA market significantly.

Among the recently launched and upcoming therapies, upadacitinib and filgotinib have the potential to impact the market owing to more selective oral JAK1 inhibitors and better clinical profile compared to already approved JAKi. Although upadacitinib will have a slight edge over filgotinib owing to order of entry, slightly better efficacy data, and recent FDA rejection of filgotinib.

To know how the trends will be impacting the market, click on the link to download the sample: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

Story continues

Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory autoimmune disease and is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints. Even after years of research, the cause of rheumatoid arthritis is still unknown. Rheumatoid Arthritis symptoms include joint pain, stiffness, swelling, and decreased movement of the joints. Rheumatoid arthritis diagnosis is done by a combination of patient's symptoms, results of doctor's examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of Rheumatoid Arthritis -specific autoantibodies. Rheumatoid Arthritis has a predilection to affect women, that's why the incidence and prevalence rates in women for RA is 2- 3 times more as compared to men. The total prevalent cases of Rheumatoid Arthritis in the 7MM were observed to be 4,356,793 in 2017 which are estimated to rise during the study period (20172030). The United States accounted for the highest number of cases in the 7MM.

The report provides an in-depth historical and forecasted analysis of Rheumatoid Arthritis Epidemiology segmented by:

Total Prevalent Cases

Total Diagnosed Prevalent Cases

Gender-specific Prevalent Cases

Age-specific Prevalent Cases

Severity-specific Prevalent Cases

Patients on targeted therapies

Line-Wise Treated Cases

Rheumatoid Arthritis Treatment Market

The Rheumatoid Arthritis treatment paradigm includes medicine, supportive treatment and surgery. Currently, there are three primary treatment options for severe and advancing Rheumatoid Arthritis which include DMARDs, NSAIDs, and corticosteroids. Rheumatoid market consists of many different drug target agents forming different drug classes. Conventional DMARDs are a group of drugs (i.e. methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) that have been shown to affect the underlying cause of RA by damping down over-activity of the immune system, which helps to ease pain, swelling and stiffness, and prevent changes occurring within the joint. Among csDMARDS, methotrexate (MTX) is considered as a part of the first treatment strategy. MTX remains the anchor drug in RA; along with usage as monotherapy, it is also the basis for combination therapies, either with GC or with other csDMARDs, bDMARDs or tsDMARDs.Patients refractory to csDMARDS or with severe symptoms usually treated with a wide variety of biologics DMARDs classes like anti-TNF, T cell inhibitor, B cell Inhibitor, Interleukin Inhibitors and targeted synthetic DMARDs like JAK Inhibitors. The drug classes include blockbusters Anti-TNF (Etanercept, Infliximab, Adalimumab, Certolizumab-pegol) JAK inhibitors (tofa citinib, baricitinib, upadacitinib, Peficitinob) B-cell inhibitors (Rituximab), Interleukin Inhibitors (Tocilizumab, Sarilumab), T-cell inhibitors (Abatacept), DMARDs, other novel inhibitors, etc.

Biological DMARDs showed promising results in treating RA patients and market penetration is expected to be more in the future and this class is expected to drive the growth of the market. Oral classes such as JAKi and upcoming BTKi due to patient convenient RoA are also expected to contribute to the Rheumatoid Arthritis market growth. The market for Rheumatoid Arthritis possesses fierce competition but still, there is a high demand for new therapies having similar or better efficacy, however, improved safety profile as well as patient adherence. Because of high competition, the new entrants are expected to be met with some resistance and will experience slow uptake, as the market is currently dominated by the anti-TNFs and entry of biosimilars will further pose significant challenges to new and upcoming treatment. It goes without saying that the dynamics of the Rheumatoid Arthritis market is expected to change because of the launch of emerging therapies, companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Gilead and Galapagos NV [Filgotinib (GS-6034; Jyseleca)], and R-Pharm (Olokizumab) with their key candidates are in registrational or late clinical-stage. In addition to this, companies like Merck KGaA (Evobrutinib), Pfizer (PF-06650833, and PF-06651600), Roche (Fenebrutinib), and several others in phase II clinical development stage with their investigational candidates.

As many potential therapies are being investigated for the management of Rheumatoid Arthritis, it is for sure that the treatment space will experience a significant impact during the forecast period of 20202030.

As the emerging drugs will be entering the market, to know what will be their impact on the existing market, which drug will be a blockbuster, and for which line of treatment these drugs will be used? Download the RA Report to know more:- https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market

Scope of the Report

Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.

Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).

Markets Segmentation: By Geographies, By Therapies (Forecasted + Historical).

Companies Covered: GlaxoSmithKline, Gilead, Galapagos NV, R-Pharm, Taisho Pharmaceuticals, Aclaris Therapeutics, Viela Bio, Bristol Myers Squibb, AbbVie, Pfizer, Philogen, Akros Pharma, Japan Tobacco, Merck KGaA, Genentech, Mesoblast, UCB Pharma, PRA HEALTH SCIENCES, Izana Bioscience, Takeda, Abivax S.A, Hope Biosciences, Genosco (Oscotec) and several others.

Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis

Market trends, pipeline analysis across different stages of development (Phase III and Phase II), and market size by therapies.

Tools used such as SWOT analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.

Case Studies

KOL's Views

Analyst's View

Table of Contents

1. Key Insights

2. Executive Summary of Rheumatoid Arthritis

3. SWOT Analysis of Rheumatoid Arthritis

4. Rheumatoid Arthritis Market Share (%) Distribution Overview at a Glance: By Country

5. Rheumatoid Arthritis Market Share (%) Distribution Overview at a Glance: By Class

6. Rheumatoid Arthritis Disease Background and Overview

7. Rheumatoid Arthritis Epidemiology and Patient Population

8. Rheumatoid Arthritis Epidemiology Scenario: 7MM

9. The United States Rheumatoid Arthritis Epidemiology

10. EU-5 Rheumatoid Arthritis Epidemiology

10.1. Germany

10.2. France

10.3. Italy

10.4. Spain

10.5. The United Kingdom

11. Japan Rheumatoid Arthritis Epidemiology

12. Current Rheumatoid Arthritis Treatment Practices

12.1. Medications

12.2. Supportive Treatment

12.3. Surgery

12.4. Treatment Algorithm

12.5. Guideline of Rheumatoid Arthritis

13. Unmet Needs

14. Patient Journey of Rheumatoid Arthritis

15. Key Endpoints in Rheumatoid Arthritis Clinical Trials

16. Rheumatoid Arthritis Marketed Therapies

16.1. Marketed Therapies Key Cross

16.2. Olumiant (Barticinib): Eli Lilly and Company/Incyte Corporation

16.3. Rinvoq (Upadacitinib): AbbVie

16.4. Xeljanz (Tofacitinib): Pfizer/PV PRISM CV

16.5. Remicade (Infliximab): Janssen Biotech (Centocor)

16.6. Enbrel (Etanercept): Immunex/Amgen

16.7. Rituxan/MabThera (Rituximab): Genentech/Biogen

16.8. Certolizumab-pegol (Cimzia): UCB Inc.

16.9. Golimumab (Simponi): Janssen Biotech

16.10. Humira (adalimumab): AbbVie

16.11. Orencia (Abatacept): Bristol Myers Squibb

16.12. Smyraf (Peficitinib): Astella Pharma

16.13. Actemra (Tocilizumab): Roche

16.14. Kineret (Anakinra): Swedish Orphan Biovitrium (SOBI)

16.15. Kevzara (Sarilumab): Regeneron and Sanofi

17. Rheumatoid Arthritis Emerging Therapies

17.1. Key Cross

17.2. GSK3196165 (otilimab/MOR103): GlaxoSmithKline

17.3. Filgotinib (GS-6034; GLPG0634; Jyseleca): Gilead and Galapagos NV

17.4. Olokizumab: R-Pharm

17.5. TS-152 (Ozoralizumab): Taisho Pharmaceuticals

17.6. ATI-450 (CDD-450): Aclaris Therapeutics

17.7. VIB4920: Viela Bio

17.8. Branebrutinib: Bristol Myers Squibb

17.9. ABBV-3373 and ABBV-154: AbbVie

17.10. Dekavil (F8IL10): Pfizer/Philogen

17.11. PF-06651600 (Ritlecitinib): Pfizer

17.12. JTE 051: Akros Pharma/Japan Tobacco

17.13. Evobrutinib (M2951): Merck KGaA

17.14. PF-06650833: Pfizer

17.15. Fenebrutinib (GDC-0853, RG7845): Genentech (subsidiary of Roche)

17.16. MPC-300-IV (Allogeneic Mesenchymal Precursor Cells): Mesoblast

17.17. Bimekizumab: UCB Pharma/PRA HEALTH SCIENCES

17.18. Namilumab (IZN-101; AMG203): Izana Bioscience/Takeda

17.19. ABX464: Abivax S.A.

17.20. HB-AdMSCs: Hope Biosciences

17.21. SKI-O-703: Genosco (Oscotec)

18. Conjoint Analysis of Rheumatoid Arthritis

More here:
Rheumatoid Arthritis Market expected to increase with a decent CAGR of approx. 3% during the study period 2017-30 - Yahoo Finance

Anterior cruciate ligament, or ACL, injuries are one of the most common types of knee injury and occur particularly in athletes or people who exercise and play sport regularly. ACL injuries can be treated surgically or non-surgically, depending on the patient, but may lead to an increased risk of osteoarthritis in later life. A new study, published in October 2020 in Scientific Reports, suggests that production of a certain protein in the knee joint following ACL injury may indicate an increased risk of osteoarthritis in future, allowing clinicians to better predict and treat this condition at an earlier stage.

What is ACL injury?

The ACL is one of the ligaments in the knee, and helps to move the joint back and forward. It is most commonly injured during running or playing sport: injuries to the ACL are known as sprains or tears. They can range from being mild, where the ligament is just stretched, to severe, where it is completely torn in two.

Patients may become aware of their knee making a popping noise, suddenly giving way, being painful, swelling and/or not moving properly. ACL injury can usually be diagnosed on examination by a doctor, but imaging may be required to ascertain the severity of the injury.

Treatment of ACL injury

If the patient wishes to return to full mobility, ACL injuries tend to require surgery as the ligament cannot repair itself. This can usually be done via arthroscopy (commonly known as keyhole surgery), which is less invasive and has a quicker recovery time compared to open surgery. For some elderly or very inactive patients, who do not need to return to great knee mobility, surgery may not be required and they may be able to use a brace and/or have physiotherapy instead if the injury is not very severe.

ACL injury and osteoarthritis

Unfortunately, patients who suffer an ACL injury also have a higher risk of developing arthritis, and in particular osteoarthritis, in the knee as they grow older. Osteoarthritis, also known as wear-and-tear arthritis, is common in elderly people, and occurs when the surface of the joint wears away, causing pain, swelling and loss of mobility.

Osteoarthritis cannot be cured but can be treated and prevented from worsening through medications, lifestyle changes such as diet and exercise, and, in some cases, surgery.

The recent study in Scientific Reports has suggested that production of a specific protein that helps lubricate the knee joint may be a predictor of future arthritis in patients with ACL injury. The study was conducted on dogs that had suffered ACL injury but the protein, called lubricin, is present in healthy knee joints in all mammals, including humans. The results may therefore be useful in treating human patients as well, and further studies are taking place to confirm if this is the case.

The study found that levels of lubricin significantly increased in those dogs that had suffered an ACL tear, before any other signs of arthritis were detected. The researchers concluded that increased levels of this protein may therefore be a marker for predicting osteoarthritis earlier, thus allowing patients to seek treatment more promptly and to make the lifestyle changes that could prevent their osteoarthritis from deteriorating.

This study is an encouraging example of how research can aid the development of treatment for common injuries and prevent subsequent and damaging side-effects later on in life.

Read this article:
ACL injury and osteoarthritis: causes, symptoms and treatment - Lexology

CMI presents an in-depth overview of the Global Rheumatoid Arthritis Treatment Market Study, detailing the latest product/industry coverage and market forecasts and status by 2027. Market research is categorized as a key area to accelerate marketization. The current market is evolving its presence and some of the major players in the study are Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

This study focuses on the Global Rheumatoid Arthritis Treatment Market status, future forecast, growth opportunity, key market, and emerging players. The study objectives are to present the Rheumatoid Arthritis Treatment growth in Key regions. In order to provide valuable insight into each key element of the market, the highest and slowest growing market segment in the study is described. Newmarket participants are emerging and are accelerating the transition in the antistatic market. Merger and acquisition activities are expected to change the market environment for this industry.

You Keep Your Social Distance And We Provide You A Social DISCOUNT Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On All CMI Reports.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/166

The Global Rheumatoid Arthritis Treatment is segmented by:

By Product Type: Global Rheumatoid Arthritis Treatment Market, By Application.

Regional Markets: United States, Europe, China, Japan, Southeast Asia, India & Central & South America

List of Companies Mentioned: Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

1) Does Study provide Latest Impact on Market due to COVID & Slowdown?

Yes, the study has considered a chapter on Impact Analysis and this 2020 Edition of the report provides detailed analysis and its impact on growth trends and market sizing to better understand the current scenario.

2) How companies are selected or profiled in the report?

The list of some players that are profiled in the report includes Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,.. the list is sorted to come up with a sample size of at least 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Is it possible to narrow down business segments by Application of this study?

Yes, depending upon the data availability and feasibility check by our Research Analyst, a further breakdown in business segments by end-use application in relation to type can be provided (If applicable) by Revenue Size or Volume*.

4) What is the base year of the study? What time frame is covered in the report?

Furthermore, the years considered for the study are as follows:

Historical year 2014-2019

Base year 2019

Forecast period** 2020 to 2027 [** unless otherwise stated]

Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On This Reports

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/166

** We will also include opportunities to utilize in micro markets that stakeholders can invest in, a detailed analysis of key competitors, and key services. **

Global Rheumatoid Arthritis Treatment Market What to expect from this report:

Focused Study on Niche Strategy and Market Development & penetration Scenario

Top 10 Global Rheumatoid Arthritis Treatment Companies in Global Market Share Analysis: Leaders and Laggards in 2017, 2019

Gain strategic insights on competitor information to formulate effective R&D moves

Identify emerging players and create effective counter-strategies to outpace competitive edge

Identify important and diverse product types/services offering carried by major players for market development

And many more .

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: Global Rheumatoid Arthritis Treatment MarketLandscape

PART 06: Global Rheumatoid Arthritis TreatmentMarket Sizing

PART 07: Global Rheumatoid Arthritis TreatmentMarket Segmentation

PART 08: CUSTOMER LANDSCAPE

PART 10: DECISION FRAMEWORK

PART 09: REGIONAL LANDSCAPE

PART 11: MARKET DYNAMICS: DRIVERS, TRENDS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/166

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

**Be Safe and Stay Home**

Visit link:
Rheumatoid Arthritis Treatment Market Opportunity and Business Industry By Forecast to 2026 | Coherent Market Insights.com - re:Jerusalem

A new report by XploreMR takes a deep dive into the Rheumatoid Arthritis Diagnosis Tests Market after conducting meticulous research, assessing each microscopic aspect of the market. The researches have connected the dots with minuscule details that shape into an intricate, immaculate yet elucidate study. The report presents a thoroughly scrutinized study of the Rheumatoid Arthritis Diagnosis Tests Market, leaving no stone unturned in offering market players a valuable and constructive tool that navigates them in the profitable path with the right set of objectives.

Following the methodology of Porters Five Forces analysis, the report emphasizes macro concepts such as the threat of new entries in the Rheumatoid Arthritis Diagnosis Tests Market, supplier power, threat of substitution, and buying power. Dwelling deeper into each of the factors, details about the competitive landscape, strategies of leading market players, and changes in the landscape, are also analyzed. In addition to competitive analysis, the researchers have also employed PESTEL analysis to study the impact of political, economic, social, technological, environmental, and legal factors on the keyword, thus leaving no loose ends.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/336

The researchers have studied the factors that are expected to drive the growth of the Rheumatoid Arthritis Diagnosis Tests by creating revenue opportunities, directly and indirectly. Similarly, the emerging trends, both long-term and short-term, present factors that are likely to impact the markets growth and project the direction the whole market is moving. Economical, technological, or any other trend that could bestow opportunities, have been studied. Moreover, the researchers have expanded the analysis beyond growth prospects and analyzed the possible restraining factors to the growth of the Rheumatoid Arthritis Diagnosis Tests Market, thus enabling market players to foresee the likely challenges and emerge successful through the forecast period 2017 2025.

In addition to the macro-economic factors that drive the global market, the market divulges micro-economic factors, diving into each individual segment such as geographical, end-use segments, and products, among others, and studies each of the segments with respect to different geographies. The geography-specific insights paint a crystal clear picture of the growth of every individual segment studied in the report, thereby enabling regional market players to leverage the trends in the region.

The report assesses key players in the Rheumatoid Arthritis Diagnosis Tests Market, studying their services, strategies, landmarks, growth plans, and recent developments. By studying multiple organizations covering small, medium, and large players the report enables emerging players to equip themselves with knowledge of competition scenarios. The most critical aspect in the competitive landscape individual growth strategy is studied extensively by dwelling into the foregoing growth trajectory of the organization. Moreover, the study paints a picture of the individual standpoints of the players in the years to come, considering the drivers and trends.

To breakdown the vast study that spreads through geographies, products, and end-use segments, among other market-specific segments, the authors present CAGR (Compound Annual Growth Rate) of each segment throughout the years of forecast. CAGR is a simplistic representation of growth that clearly projects which segment registered the highest/least growth through the forecast period 2017 2025. Moreover, each segment is analyzed on the basis of volume and volume, also projected with year-on-year growth and CAGR.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/336

Researchers also present production and consumption analysis, key findings, important suggestions and recommendations, and other aspects, thus offering a comprehensive picture of the Rheumatoid Arthritis Diagnosis Tests Market to bolster market players in planning their strategies in the years to come.

Important Questions Answered

Highlights of TOC:

Overview: Presents a broad overview of the Rheumatoid Arthritis Diagnosis Tests market, acting as a snapshot of the elaborate study that follows.

Market Dynamics: A straight-forward discussion about key drivers, restraints, challenges, trends, and opportunities of the Rheumatoid Arthritis Diagnosis Tests market.

Product Segments: Explores the market growth of the wide variety of products offered by organizations, and how they fare with end-users.

Application Segments: This section studies the key end-use applications that contribute to the market growth and the emerging opportunities to the Rheumatoid Arthritis Diagnosis Tests market.

Geographical Segments: Each regional market with a region-specific study of each segment- is carefully assessed for understanding its current and future growth scenarios.

Company Profiles: Leading and emerging players of the Rheumatoid Arthritis Diagnosis Tests Market are thoroughly profiled in the report based on their market share, market served, products, applications, regional growth, and other factors.

Get Full Report Access athttps://www.xploremr.com/cart/336/SL

Why Do Companies Trust XMR?

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis

Contact us:

XploreMR

111 North Market Street, Suite 300,

San Jose, CA 95113, United States

Ph.No: +16692840108

E-mail id- [emailprotected]

Web: https://xploremr.com

See the original post here:
Rheumatoid Arthritis Diagnosis Tests Market Projection By Top key Players, Share, Size, Demand, Opportunities, Sale Area, Revenue Analysis Forecast To...

Global Rheumatoid Arthritis Treatment Market Research Report offers a in-depth view on market trends, forecast statistics, company profile, growth drivers and latest industry insights. The report covers all the Rheumatoid Arthritis Treatment type, applications, deployment models, research regions. A deep-dive analysis on leading Rheumatoid Arthritis Treatment industry players, their market share, production volume, gross margin analysis from 2015-2019 is provided. Challenges to the Rheumatoid Arthritis Treatment development, growth opportunities, market drivers, restraints are described in this report.

The market value, market share, production and gross margin of Rheumatoid Arthritis Treatment is covered for every type, application, and geographical regions. Also, import-export scenario, regional SWOT analysis, and market status is elaborated. Rheumatoid Arthritis Treatment Forecast covers type, application and regional forecast for market value, volume, and consumption from 2020 to 2026. Industry barriers, investment feasibility, and opportunities to the new Rheumatoid Arthritis Treatment market players are analyzed in this report.

Global Rheumatoid Arthritis Treatment market is subdivided based on type, application and research regions. Top regions studied in this report include North America, Europe, Asia-Pacific, South America, Middle East & Africa. For each region, production value and growth rate is covered from 2015 to 2019. The information on market concentration and market maturity analysis will lead to investment feasibility.

Get Free Sample(COVID-19 Impact Analysis Updated Sample):@:

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#request_sample

Major players covered in this report:

Johnson & JohnsonAmgen Inc.Sobi Inc.UCB S.A.Eli Lilly & CompanySanofi SAAbbVie Inc.Pfizer Inc.Bristol-Myers Squibb CompanyF. Hoffman-La Roche AG

Global Rheumatoid Arthritis Treatment Market Segmentation:

By Type:

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)CorticosteroidsDisease-modifying anti-rheumatic drugs (DMARDs)

By Application:

HospitalRetail PharmaciesDrugstores

Market drivers explain the emerging countries and Rheumatoid Arthritis Treatment growth. Also, the limitations, opportunities, latest industry plans, and policies are offered. Industry chain analysis explains upstream raw material suppliers, key market players, production process analysis, Rheumatoid Arthritis Treatment manufacturing cost structures, and global market share of Rheumatoid Arthritis Treatment in 2019. This in-depth study explains the cost of raw materials, labor cost, marketing channels and major downstream buyers of Rheumatoid Arthritis Treatment.

Get Up to 30% Off on purchasing this report, Ask Here for Discount @:

https://www.globalmarketers.biz/discount_inquiry/discount/146290

This study analyzes the Rheumatoid Arthritis Treatment industry market status and forecast statistics explaining the production, revenue, consumption ratio, and historic market trends. All the manufacturers, market share, company profiles, production capacity, and gross margin analysis of Rheumatoid Arthritis Treatment is presented in this report. The industry breakdown based on product type, applications, regions, and manufacturer will provide sophisticated Rheumatoid Arthritis Treatment market view. Recent Rheumatoid Arthritis Treatment developments, opportunities, challenges, and business strategies are explained. The influencing factors, product launches, mergers and acquisition of Rheumatoid Arthritis Treatment is covered in this study.

The report also explains the demand and supply side of Rheumatoid Arthritis Treatment, revenue estimates, competitive scenario, and sales data. Rheumatoid Arthritis Treatment value chain, market status, and price trends are explained in detail. Rheumatoid Arthritis Treatment industry presence across different geographies covers the regions like North America, Europe, Asia-Pacific, Middle East & Africa, and South America. Further, the countries like United States, Canada, Mexico, China, Japan, Korea, India, Australia, Indonesia, Singapore, Germany, United Kingdom, France, Italy, Spain, Russia, Brazil, Argentina, UAE, Saudi Arabia, Turkey and the rest are analyzed in this report.

Enquire For Complete Sample Report Copy Or Request For Customization:

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#inquiry_before_buying

Reasons To Buy This Report:

Rheumatoid Arthritis Treatment Report Effectively Addresses The Below Queries.

Explore Detailed Table Of Content With Table Of Figures: @

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#table_of_contents

Visit link:
Global Rheumatoid Arthritis Treatment Market Expected To Witness The Highest Growth 2027 | Johnson & Johnson, Amgen Inc., Sobi Inc., UCB SA, Eli...

Non-contact, high-resolution imaging for uveitis surveillance in juvenile idiopathic arthritis (JIA) is feasible and acceptable to patients with the disease, according to study results published in Arthritis & Rheumatology.

Disease activity in anterior uveitis is traditionally assessed using slit lamp biomicroscopy; however, this modality is semiquantitative and image interpretation is subjective. Optical coherence tomography (OCT) may represent a better metric of measuring inflammatory disease, with recent modifications to OCT allowing the imaging of the anterior chamber.

In the current study, researchers sought to assess the feasibility and accuracy of cross-sectional anterior segment OCT (AS-OCT) for the diagnosis of active uveitis in JIA.

In the cross-sectional observational study, the researchers enrolled children with and without uveitis from a specialist pediatric uveitis center in England between 2017 and 2018. The 2 groups of participants included children with JIA and a diagnosis of chronic anterior uveitis; and children without both JIA and uveitis. All children received routine clinical assessment of the anterior chamber with a slit lamp. The ordinal Standardized Uveitis Nomenclature (SUN) anterior chamber activity cell count grade was used to diagnose inflammation.

The AS-OCT scans of the anterior chamber were then acquired. Patients were asked to focus their eye that was being tested on the machine fixation beam. Image acquisition time was measured, and participants were asked to rate the acceptability of the acquisition process. The AS-OCT images were analyzed manually for the presence of anterior chamber inflammation. Examiners were blinded to the results of the initial clinical examination. Correlation between imaging-acquired cell count and clinical assessment was calculated using a multilevel linear regression model. Sensitivity, specificity, and repeatability were also reported.

A total of 26 children received AS-OCT imaging, among whom 18 (69.2%) were girls. Median age was 8 years (age range, 3-15 years). Twelve children had active anterior inflammation during their initial clinical examination. Time taken to acquire AS-OCT images from both eyes ranged from 1.5 to 22 minutes, with a median value of 8 minutes. Patients rated image acquisition acceptability as high, with a median visual analog scale score of 9.5 of a possible 10.

Intraobserver image agreement was high with regard to manual cell count (intraclass observer coefficient, 0.81; 95% CI, 0.63-0.98). There was moderate agreement on cell count between observers (kappa statistic [], 0.46; 95% CI, 0.28-0.63), and between-observer disagreement on the presence of intraocular cells in 25 of the 377 reviewed images (6.6%). Anterior segment OCT had high correlation with active inflammation as diagnosed by slit lamp examination. Sensitivity for active inflammation was 91.7% (95% CI, 61.5%-99.8%); specificity was 85.7% (95% CI, 57.2%-89.2%); and accuracy was 88.5% (95% CI, 69.9%-97.6%). In multilevel regression modeling, there was high positive correlation between clinical assessment and image-based cell count (coefficient, 3.3; 95% CI, 1.3-5.2; P =.002). No children without uveitis had a positive result on AS-OCT imaging.

These results support the feasibility and acceptability of AS-OCT imaging for the assessment of uveitis in children with JIA.

The primary study limitation was the small sample size and the fact that the study results may not be generalizable to all children with anterior chamber inflammation. While AS-OCT correlated well with slit lamp examination, further study is necessary to standardize the imaging protocol.

Imaging-based metrics for uveitis holds the promise of providing sensitive, robust, validated measurement of disease status which, alongside [standardized] datasets and patient[-centered] metrics, can also improve service provision, prognostication and precision in disease management for affected or at-risk children, the researchers concluded.

Akbarali S, Rahi JS, Dick AD, et al. Imaging based uveitis surveillance in juvenile idiopathic arthritis: feasibility, acceptability and diagnostic performance. Arthritis Rheumatol. Published online September 25, 2020. doi:10.1002/art.41530

View original post here:
Imaging-Based Uveitis Surveillance Feasible for Patients With Juvenile Idiopathic Arthritis - Rheumatology Advisor

Objective:To compare the efficacy and safety of brodalumab, an interleukin-17 receptor subunit A inhibitor, with placebo, in patients with psoriatic arthritis (PsA).

Methods:Adult patients with active PsA and inadequate response to, or intolerance to, conventional treatment were enrolled into two phase III studies (NCT02029495andNCT02024646) and randomised 1:1:1 to receive subcutaneous brodalumab 140 mg or 210 mg or placebo at weeks 0, 1 and every 2 weeks up to 24 weeks. About 30% of patients had prior use of biologics. The primary endpoint for both studies was the American College of Rheumatology 20 (ACR20) response at week 16.

Results:962 patients were randomised across the studies prior to early termination due to sponsor decision. The primary endpoint was met in both studies. Based on comparable design and eligibility criteria, data from both studies were pooled. Significantly more patients achieved ACR20 at week 16 in both brodalumab treatment groups (45.8% and 47.9% for 140 mg and 210 mg, respectively) versus placebo (20.9%) (p<0.0001). Similar results were observed at week 24. Significantly higher proportions of patients receiving brodalumab achieved ACR50/70, Psoriasis Area and Severity Index 75/90/100 and resolution of dactylitis and enthesitis versus placebo (p<0.01). Adverse event rates were similar across treatments at week 16 (54.4%, 51.6% and 54.5% for placebo, brodalumab 140 mg and 210 mg, respectively). No new safety signals were reported.

Conclusion:Brodalumab was associated with rapid and significant improvements in signs and symptoms of PsA versus placebo. Brodalumab was well tolerated, with a safety profile consistent with other interleukin-17 inhibitors.

Keywords:DMARDs (biologic); autoimmune diseases; psoriatic arthritis.

Go here to read the rest:
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials - DocWire News

- Researchers to share updates on long-term safety and efficacy of RINVOQ for the treatment of moderate to severe rheumatoid arthritis

- Presentations to highlight patient-reported outcomes of RINVOQ in people living with psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis

- New safety and efficacy data of RINVOQ through 64 weeks in treating ankylosing spondylitis, as well as an integrated safety analysis for psoriatic arthritis, will also be presented

NORTH CHICAGO, Ill., Oct. 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of new data on RINVOQ (upadacitinib) and HUMIRA (adalimumab) across multiple rheumatic diseases at the American College of Rheumatology's annual meeting (ACR Convergence 2020), to be held virtually November 5-9. A total of 38 abstracts, including seven oral presentations, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

"At AbbVie, we have a focused vision of improving the care and advancing treatment options for people living with rheumatic diseases, which is illustrated by the body of research that will be presented at this year's ACR meeting," said Marek Honczarenko M.D., Ph.D., vice president, global immunology development, AbbVie. "These data underscore the potential for RINVOQ and HUMIRA to help more people living with rheumatic diseases reach their goals."

Data evaluating the long-term safety and efficacy of RINVOQ in rheumatoid arthritis will be presented, including:

84-week data on RINVOQ as a monotherapy in patients with inadequate response to methotrexate

72-week RINVOQ monotherapy data in methotrexate-nave patients

72-week data comparing RINVOQ versus HUMIRA in patients with inadequate response to methotrexate

An integrated safety update reflecting up to three years of treatment with RINVOQ

Oral presentations will also highlight the safety and efficacy of RINVOQ in the treatment of psoriatic arthritis (through 24 weeks) and ankylosing spondylitis (through 64 weeks), while a poster presentation will provide a new integrated safety analysis from two Phase 3 trials evaluating the safety profile of RINVOQ in psoriatic arthritis.

Story continues

Further, several presentations will show patient-reported outcomes for RINVOQ in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, including its impact on pain reduction and physical function.

Key AbbVie rheumatology abstracts in the ACR Convergence 2020 program include:

Rheumatoid Arthritis

Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis. SB Cohen, et al. Abstract Number: 0237; Poster Session: Friday, November 6, 9 11 a.m. EST

Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks. R Fleischmann, et al. Abstract Number: 0212; Poster Session: Friday, November 6, 9 11 a.m. EST

Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks. JS Smolen, et al. Abstract Number: 0209; Poster Session: Friday, November 6, 9 11 a.m. EST

Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program. E Choy, et al. Abstract Number: 0215; Poster Session: Friday, November 6, 9 11 a.m. EST

Upadacitinib Monotherapy in Methotrexate-nave Patients with Rheumatoid Arthritis: Results at 72 Weeks. R van Vollenhoven, et al. Abstract Number: 0207; Poster Session: Friday, November 6, 9 11 a.m. EST

Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study. E Mysler, et al. Abstract Number: 0228; Poster Session: Friday, November 6, 9 11 a.m. EST

Radiographic Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib as Monotherapy or in Combination with Methotrexate: Results at 2 Years. CG Peterfy, et al. Abstract Number: 1231; Poster Session: Sunday, November 8, 9 11 a.m. EST

Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study. M Bergman, et al. Abstract Number: 1728; Poster Session: Monday, November 9, 9 11 a.m. EST

Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study. K Winthrop, et al. Abstract Number: 1996; Oral Presentation: Monday, November 9, 10 10:50 a.m. EST

Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib. K Winthrop, et al. Abstract Number: 2002; Oral Presentation: Monday, November 9, 3 3:50 p.m. EST

Psoriatic Arthritis

Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial. MC Genovese, et al. Abstract Number: 0504; Oral Presentation: Friday, November 6, 3 3:50 p.m. EST

Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs. IB McInnes, et al. Abstract Number: 0896; Poster Session: Saturday, November 7, 9 11 a.m. EST

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study. V Strand, et al. Abstract Number: 1341; Poster Session: Sunday, November 8, 9 11 a.m. EST

Improvement in Patient-Reported Outcomes for Upadacitinib Versus Placebo Among Patients With Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs. V Strand, et al. Abstract Number: 1371; Poster Session: Sunday, November 8, 9 11 a.m. EST

Safety Profile of Upadacitinib in Psoriatic Arthritis: Integrated Analysis From Two Phase 3 Trials. GR Burmester, et al. Abstract Number: 1350; Poster Session: Sunday, November 8, 9 11 a.m. EST

Characterization of Remission in Patients with Psoriatic Arthritis Treated with Upadacitinib: Post-hoc Analysis from Two Phase 3 Trials. P Mease, et al. Abstract Number: 1355; Poster Session: Sunday, November 8, 9 11 a.m. EST

Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial. IB McInnes, et al. Abstract Number: 2026; Oral Presentation: Monday, November 9, 11 11:50 a.m. EST

Ankylosing Spondylitis

Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs. A Deodhar, et al. Abstract Number: 0369; Poster Session: Friday, November 6, 9 11 a.m. EST

Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension. A Deodhar, et al. Abstract Number: 2023; Oral Presentation: Monday, November 9, 11 11:50 a.m. EST

A full list of all 38 AbbVie abstracts accepted for presentation at ACR Convergence 2020 can be found here.

About RINVOQ (upadacitinib)Discovered and developed by AbbVie, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1-3 In August 2019, RINVOQ received U.S. Food and Drug Administration approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, RINVOQ was approved by the European Commission for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. The approved dose for RINVOQ in rheumatoid arthritis is 15 mg. Phase 3 trials of RINVOQ in psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, Crohn's disease, atopic dermatitis, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.4-12 Use of RINVOQ in ankylosing spondylitis and psoriatic arthritis is not approved and its safety and efficacy have not been established by regulatory authorities.

Important Safety Information about RINVOQ (upadacitinib)13

RINVOQ U.S. Use and Important Safety InformationRINVOQ is a prescription medicine used to treat adults with moderate to severe rheumatoid arthritis in whom methotrexate did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children under 18 years of age.

What is the most important information I should know about RINVOQ?RINVOQ is a medicine that can lower the ability of your immune system to fight infections. You should not start taking RINVOQ if you have any kind of infection unless your healthcare provider (HCP) tells you it is okay.

Serious infections have happened in some people taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your HCP should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You may be at higher risk of developing shingles (herpes zoster).

Lymphoma and other cancers, including skin cancers, can happen in people taking RINVOQ.

Blood clots in the veins of the legs or lungs and arteries are possible in some people taking RINVOQ. This may be life-threatening and cause death.

Tears in the stomach or intestines and changes in certain laboratory tests can happen. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results.

What should I tell my HCP BEFORE starting RINVOQ?Tell your HCP if you:

Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection such as:

Have TB or have been in close contact with someone with TB.

Have had any type of cancer, hepatitis B or C, shingles (herpes zoster), or blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines.

Have other medical conditions including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system.

Live, have lived, or have traveled to parts of the country that increase your risk of getting certain kinds of fungal infections, such as the Ohio and Mississippi River valleys and the Southwest. If you are unsure if you've been to these areas, ask your HCP.

Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines.

Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant while taking RINVOQ and for at least 4 weeks after your last dose.

Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. You should not breastfeed while taking RINVOQ and for at least 6 days after your last dose.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.

Especially tell your HCP if you take:

Ask your HCP or pharmacist if you are not sure if you are taking any of these medicines.

What should I tell my HCP AFTER starting RINVOQ?Tell your HCP right away if you:

Have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse.

Have any signs or symptoms of blood clots during treatment with RINVOQ, including:

Have a fever or stomach-area pain that does not go away, and a change in your bowel habits.

What are the common side effects of RINVOQ?These include: upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. These are not all the possible side effects of RINVOQ.

RINVOQ is taken once a day with or without food. Do not split, break, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it.

This is the most important information to know about RINVOQ. For more information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

Please click here for the Full Prescribing Information and Medication Guide.

About HUMIRA in the U.S.

UsesHUMIRA is a prescription medicine used:

To reduce the signs and symptoms of:

In adults, to help get moderate to severe ulcerative colitis (UC) under control (induce remission) and keep it under control (sustain remission) when certain other medicines have not worked well enough. It is not known if HUMIRA is effective in people who stopped responding to or could not tolerate anti-TNF medicines.

To treat moderate to severe chronic plaque psoriasis (Ps) in adults who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.

To treat non-infectious intermediate (middle part of the eye), posterior (back of the eye), and panuveitis (all parts of the eye) in adults and children 2 years of age and older.

Important Safety InformationHUMIRA is a TNF blocker medicine that affects the immune system and can lower the body's ability to fight infections. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. People should be tested for TB before HUMIRA use and monitored for signs and symptoms of TB during therapy, even if their TB test was negative. People at risk of TB may be treated with medicine for TB. Treatment with HUMIRA should not be started in a person with an active infection, unless approved by a doctor. HUMIRA should be stopped if a person develops a serious infection. People should tell their doctor if they live in or have been to a region where certain fungal infections are common, as these infections may happen or become more severe if people use HUMIRA. People should tell their doctor if they have had TB or hepatitis B, are prone to infections, or have symptoms such as fever, fatigue, cough, or sores.

For people taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers, including HUMIRA, the chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated.

Other possible serious side effects with HUMIRA include hepatitis B infection in carriers of the virus; allergic reactions; nervous system problems; blood problems; certain immune reactions, including a lupus-like syndrome; liver problems; and new or worsening heart failure or psoriasis. The use of HUMIRA with anakinra or abatacept is not recommended. People using HUMIRA should not receive live vaccines. Children should be brought up to date on all vaccines before starting HUMIRA.

Common side effects of HUMIRA include injection site reactions (redness, rash, swelling, itching, or bruising), upper respiratory infections (including sinus infections), headaches, rash, and nausea.

HUMIRA is given by injection under the skin.

The benefits and risks of HUMIRA should be carefully considered before starting therapy.

Please click here for the Full Prescribing Information and Medication Guide.

About AbbVie in RheumatologyFor more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Our longstanding commitment to discovering and delivering transformative therapies is underscored by our pursuit of cutting-edge science that improves our understanding of promising new pathways and targets in order to help more people living with rheumatic diseases reach their treatment goals. For more information on AbbVie in rheumatology, visit https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/rheumatology.html.

About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.

Forward-Looking StatementsSome statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

AbbVie Data on File. ABVRRTI70713.

AbbVie Data on File. ABVRRTI70838.

AbbVie Data on File. ABVRRTI70869.

Pipeline Our Science | AbbVie. AbbVie. 2019. Available at: https://www.abbvie.com/our-science/pipeline.html. Accessed on August 17, 2020.

Burmester G.R., et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy. ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT02365649. Accessed on August 17, 2020

A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT02819635. Accessed on August 17, 2020.

A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis (SELECT Axis 1). ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/study/NCT03178487. Accessed on August 17, 2020.

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA). ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT03725202. Accessed on August 17, 2020.

A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis. ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/record/NCT03607422. Accessed on August 17, 2020.

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (SELECT - PsA 1). ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT03104400. Accessed on August 17, 2020.

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-TAK). ClinicalTrials.gov. 2020. Available at https://clinicaltrials.gov/ct2/show/record/NCT04161898. Accessed on October 13, 2020.

RINVOQ (upadacitinib) [Package Insert]. North Chicago, Ill.: AbbVie Inc.

View original content:http://www.prnewswire.com/news-releases/abbvie-highlights-innovative-research-for-people-with-rheumatic-diseases-with-new-data-at-acr-convergence-2020-301161316.html

SOURCE AbbVie

See the original post:
AbbVie Highlights Innovative Research for People with Rheumatic Diseases with New Data at ACR Convergence 2020 - Yahoo Finance

Fact.MR has recently published a report, titled [Global Rheumatoid Arthritis Stem Cell Therapy Market 2020 by Key Countries, Companies, Type and Application]. The research report provides an in-depth explanation of the various factors that are likely to drive the market. It discusses the future of the market by studying the historical details. Analysts have studied the ever-changing market dynamics to evaluate their impact on the overall market. In addition, the report also discusses the segments present in the market. Primary and secondary research methodologies have been used to provide the readers with an accurate and precise understanding of the overall The Rheumatoid Arthritis Stem Cell Therapy market. Analysts have also given readers an unbiased opinion about the direction companies will take during the forecast period.

The research report also includes the global market figures that provide historical data as well as estimated figures. It gives a clear picture of the growth rate of the market during the forecast period. The report aims to give the readers quantifiable data that is collected from verified data. The report attempts to answer all the difficult questions such as market sizes and company strategies.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Competitive landscape

Global Rheumatoid Arthritis Stem Cell Therapy Market: Drivers and Restraints

The report explains the drivers shaping the future of the Rheumatoid Arthritis Stem Cell Therapy market. It evaluates the various forces that are expected to create a positive influence on the overall market. Analysts have studied the investments in research and development of products and technologies that are expected to give the players a definite boost. Furthermore, researchers have also included an analysis of the changing consumer behavior that is projected to impact the supply and demand cycles present in the global The Rheumatoid Arthritis Stem Cell Therapy market. Evolving per capita earnings, improving economic statuses, and emerging trends have all been studied in this research report.

The research report also explains the potential restraints present in the global The Rheumatoid Arthritis Stem Cell Therapy market. It evaluates the aspects that are likely to hamper the market growth in the near future. In addition to this assessment, it also provides a list of opportunities that could prove lucrative to the overall market. Analysts provide solutions for turning threats and restraints into successful opportunities in the coming years.

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Global Rheumatoid Arthritis Stem Cell Therapy Market: Regional Segmentation

In the successive chapters, analysts have studied the regional segments present in the global The Rheumatoid Arthritis Stem Cell Therapy market. This gives the readers a narrowed-view of the global market enabling a closer look at the elements that could define its progress. It highlights myriad regional aspects such as the impact of culture, environment, and government policies that influence the regional markets.

Global Rheumatoid Arthritis Stem Cell Therapy Market: Competitive Landscape

The last chapter of the global The Rheumatoid Arthritis Stem Cell Therapy market research report focuses solely on the competitive landscape. It studies the key players present in the market. In addition to a brief overview of the company, analysts shed light on their valuation and evolution. It also mentions the list of important products and the ones in the pipeline. The competitive landscape is analyzed by understanding the strategies of the companies and the initiatives they have taken in recent years to overcome the intensive competition.

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Read the rest here:
Innovations in the Rheumatoid Arthritis Stem Cell Therapy Field Likely to Aid the Growth of the Rheumatoid Arthritis Stem Cell Therapy Market 2018 to...

Joint pain resulting in arthritis is a common health problem and if you are suffering from arthritis, there are certain foods you need to avoid to prevent from worsening your health conditions. Find out more.

Arthritis is a common health issue that occurs in many adults and younger people. It involves inflammation in your joints that leads to weakening the bones and damaging them. Some people believe that changes in diet are related to increased symptoms in arthritis. This change might be excess of fat and sugar or avoiding foods that are high in purines.

Let us have a look at five types of food that should be avoided if you are suffering from arthritis:

Inflammatory fats

Since inflammatory fats cause inflammation in the body, they are to be avoided by people with arthritis. Foods which include Omega 6 fatty acids like oil, corn, sunflower and vegetable oil. Saturated fat like meat, butter, cheese and trans fat. Trans fat is bad for health anyway as it increases the level of bad cholesterol in the body.

Sugar

People who have processed sugar regularly in their tea or coffee are highly prone to being at risk for having heart strokes. It leads to obesity, inflammation and other chronic diseases. Limit your intake of carbonated drinks, sugar in beverages, cereal bowls and other food items.

Tomatoes, eggplant, potatoes, bell peppers

Removing these food items from your diet or as part of key ingredients in your dishes might help. This improves in reducing the chances of developing any symptoms related to arthritis.

Purines

These are foods that are high in purines, which are substances in foods that the body converts to uric acid. The uric acid can accumulate in blood causing a gout attack. These types of foods include red meat, beer, ham and seafood.

Also Read:What are Shingles and is stress the real cause? Heres all you need to know

x Your comment has been submitted to the moderation queue

Read more from the original source:
THESE are the 5 foods people who suffer from arthritis must avoid - PINKVILLA